循环肿瘤DNA揭示转移性结直肠癌抗表皮生长因子受体治疗获得性耐药的多様性
在CO.26试验的169例难治性转移性结直肠癌患者中,对比抗EGFR治疗前组织全外显子测序与基线及第8周ctDNA检测,发现既往抗EGFR治疗者(66例)出现多个基因突变频率增加、拷贝数增益及融合,多克隆耐药常见,≥10个耐药相关改变者占21%对5%(P=0.010)。
要点
- ctDNA可识别抗EGFR治疗后EGFR、KRAS、BRAF、NRAS等12个基因突变频率增加。
- 抗EGFR暴露后29个基因拷贝数增益频率显著增加,8周后无衰减。
- 既往抗EGFR治疗者中21%出现≥10个耐药相关改变,高于无治疗者的5%(P=0.010)。
核心结论
- 配对组织与ctDNA测序识别出与抗EGFR治疗相关的多个新突变、拷贝数增益和融合,这些改变常在同一患者中作为亚克隆改变共存。
研究设计与样本
- CO.26试验中169例治疗难治性转移性结直肠癌患者,接受抗EGFR治疗前组织全外显子测序,并与基线及第8周GuardantOMNI ctDNA检测对比。
- 比较既往接受抗EGFR治疗患者(n=66)与未接受者的获得性改变,抗EGFR治疗距ctDNA评估中位111天。
主要发现
- ctDNA识别12个基因在抗EGFR治疗后突变频率增加,包括EGFR(P=0.0007)、KRAS(P=0.0017)、LRP1B(P=0.0046)、ZNF217(P=0.0086)、MAP2K1(P=0.018)、PIK3CG(P=0.018)、BRAF(P=0.048)、NRAS(P=0.048)。
- 获得性突变表现为多个并发亚克隆改变,多数随时间衰减。
- 抗EGFR暴露后29个基因拷贝数增益频率显著增加,包括EGFR(P<0.0001)、SMO(P<0.0001)、BRAF(P<0.0001)、MET(P=0.0002)、FLT3(P=0.0002)、NOTCH4(P=0.0006)、ERBB2(P=0.004)、FGFR1(P=0.006),8周后拷贝数增益稳定无衰减。
- 11例患者中检出13个基因融合,除一个外均与既往抗EGFR治疗相关。
- 既往抗EGFR治疗者中21%出现≥10个耐药相关改变,无治疗者为5%(P=0.010);治疗前肿瘤突变负荷无差异(P=0.63),抗EGFR暴露增加TMB(P=0.028),无暴露者TMB下降(P=0.014)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Anti-epidermal growth factor receptor (EGFR) antibodies are effective treatments for metastatic colorectal cancer. Improved understanding of acquired resistance mechanisms may facilitate circulating tumor DNA (ctDNA) monitoring, anti-EGFR rechallenge, and combinatorial strategies to delay resistance. METHODS: Patients with treatment-refractory metastatic colorectal cancer (n = 169) enrolled on the CO.26 trial had pre-anti-EGFR tissue whole-exome sequencing (WES) compared with baseline and week 8 ctDNA assessments with the GuardantOMNI assay. Acquired alterations were compared between patients with prior anti-EGFR therapy (n = 66) and those without. Anti-EGFR therapy occurred a median of 111 days before ctDNA assessment. RESULTS: ctDNA identified 12 genes with increased mutation frequency after anti-EGFR therapy, including EGFR (P = .0007), KRAS (P = .0017), LRP1B (P = .0046), ZNF217 (P = .0086), MAP2K1 (P = .018), PIK3CG (P = .018), BRAF (P = .048), and NRAS (P = .048). Acquired mutations appeared as multiple concurrent subclonal alterations, with most showing decay over time. Significant increases in copy-gain frequency were noted in 29 genes after anti-EGFR exposure, with notable alterations including EGFR (P < .0001), SMO (P < .0001), BRAF (P < .0001), MET (P = .0002), FLT3 (P = .0002), NOTCH4 (P = .0006), ERBB2 (P = .004), and FGFR1 (P = .006). Copy gains appeared stable without decay 8 weeks later. There were 13 gene fusions noted among 11 patients, all but one of which was associated with prior anti-EGFR therapy. Polyclonal resistance was common with acquisition of ≥ 10 resistance related alterations noted in 21% of patients with previous anti-EGFR therapy compared with 5% in those without (P = .010). Although tumor mutation burden (TMB) did not differ pretreatment (P = .63), anti-EGFR exposure increased TMB (P = .028), whereas lack of anti-EGFR exposure resulted in declining TMB (P = .014). CONCLUSION: Paired tissue and ctDNA sequencing identified multiple novel mutations, copy gains, and fusions associated with anti-EGFR therapy that frequently co-occur as subclonal alterations in the same patient.
引用
- Topham JT, O'Callaghan CJ, Feilotter H, et al. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer. J Clin Oncol. 2022. PMID: 36007218. doi:10.1200/JCO.22.00364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。